Dr. Gandara’s research interests focus on developmental therapeutics of new anti-cancer agents as well as preclinical modeling and clinical research in lung cancer. He is the principal investigator on an Early Therapeutics award from the National Cancer Institute (NCI), where he leads an interdisciplinary team of clinical oncologists, pharmacologists, molecular biologists and statisticians in developing new anti-cancer agents in a variety of novel drug classes. He also leads a multi-specialty team in the Southwest Oncology Group (SWOG), an NCI-funded national clinical research organization, in studies related to improving therapies for lung cancer and developing predictive biomarkers of therapeutic efficacy.
Dr. Gandara is also the UC Davis principal investigator for a multi-institutional collaboration (iGXT: integrated Genetically-engineered mouse models, patient-derived Xenografts, and Clinical Trials) between the NCI Center for Advanced Preclinical Research (CAPR) and Jackson Laboratory, an NCI-designated basic cancer center. The goal of this iGXT project is to develop better preclinical models to optimize cancer drug development and speed the transition to personalized cancer therapy.